Azusa Komori
Matsuyama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 study.
Journal: Therapeutic advances in medical oncology
Published: June 26, 2025
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancer.
Journal: Frontiers in oncology
Published: May 11, 2025
A multicenter, prospective, observational study of nivolumab readministration for advanced gastric cancer (NIVO RETURNS).
Journal: Future oncology (London, England)
Published: May 08, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302).
Journal: Therapeutic advances in medical oncology
Published: November 21, 2024
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: October 01, 2024
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 Studies.
Journal: Oncology
Published: August 13, 2024
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 Study.
Journal: Asia-Pacific journal of clinical oncology
Published: July 25, 2024
The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma.
Journal: Scientific reports
Published: May 25, 2024
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Journal: Scientific reports
Published: March 04, 2024
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Journal: Scientific reports
Published: February 24, 2024
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
Journal: Scientific reports
Published: November 14, 2023
Last Updated: 09/26/2026